| 36.05 -0.39 (-1.07%) | 08-31 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 44.81 | 1-year : | 52.34 |
| Resists | First : | 38.36 | Second : | 44.81 |
| Pivot price | 36.94 |
|||
| Supports | First : | 33.82  |
Second : | 31.02 |
| MAs | MA(5) : | 37.22 |
MA(20) : | 36.48 |
| MA(100) : | 33.98 |
MA(250) : | 29.87 |
|
| MACD | MACD : | 0.8 |
Signal : | 0.9 |
| %K %D | K(14,3) : | 45.6 |
D(3) : | 69.6 |
| RSI | RSI(14): 51.1 |
|||
| 52-week | High : | 38.36 | Low : | 18.2 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TEVA ] has closed above bottom band by 11.4%. Bollinger Bands are 47.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 36.38 - 36.64 | 36.64 - 36.83 |
| Low: | 34.95 - 35.3 | 35.3 - 35.56 |
| Close: | 35.57 - 36.04 | 36.04 - 36.4 |
Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.
Mon, 31 Aug 2026
White House unveils next round of MFN pricing deals with 9 midsized drugmakers - Fierce Pharma
Mon, 31 Aug 2026
Teva Pharmaceutical Industries Ltd - Via Ritzau
Mon, 31 Aug 2026
Trump announces Medicaid drug pricing deals with 9 firms - The Hill
Mon, 31 Aug 2026
Donald Trump announces pharma deal: List of drugs getting prices reduced - Newsweek
Mon, 31 Aug 2026
Trump strikes new drug pricing deals with nine midsized drugmakers - cnbc.com
Mon, 31 Aug 2026
Teva Seeks to Boost Neuroscience Portfolio With BioXcel Asset Bid - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 1,170 (M) |
| Shares Float | 1,090 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 64.4 (%) |
| Shares Short | 34,320 (K) |
| Shares Short P.Month | 32,030 (K) |
| EPS | 0.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.65 |
| Profit Margin | 4 % |
| Operating Margin | 4 % |
| Return on Assets (ttm) | 5.1 % |
| Return on Equity (ttm) | 9.6 % |
| Qtrly Rev. Growth | -0.9 % |
| Gross Profit (p.s.) | 7.76 |
| Sales Per Share | 14.8 |
| EBITDA (p.s.) | 3.64 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 1,900 (M) |
| Levered Free Cash Flow | 2,220 (M) |
| PE Ratio | 60.08 |
| PEG Ratio | 1 |
| Price to Book value | 5.42 |
| Price to Sales | 2.43 |
| Price to Cash Flow | 22.19 |
| Dividend | 0.09 |
| Forward Dividend | 0 |
| Dividend Yield | 0.2% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|